The ACR hybrid score combines conventional ACR20/50/70 scores with the mean percent change in all 7 ACR core components, providing a percent improvement from baseline on a continuous scale.
RAPID 1 is a phase III double-blind placebo-controlled trial intended to determine the efficacy and tolerability of certolizumab pegol together with methotrexate (MTX), to treat active RA in patients who did not adequately respond to conventional treatment.
In the study, the ACR hybrid was combined with the conventional ACR20/50/70 scores with the mean percent change in all 7 ACR core components, providing a percent improvement from baseline on a continuous scale.
The results from this post hoc analysis suggest that certolizumab pegol plus MTX conferred greater benefit than placebo plus MTX regardless of measures according to ACR20 responder rates, ACR hybrid scores and mean changes from baseline in the DAS28.